Could a single CAR-T infusion free some from daily insulin?
NCT ID NCT07528105
First seen Apr 23, 2026 · Last updated May 25, 2026 · Updated 5 times
Summary
This early-phase study tests a one-time infusion of specially engineered immune cells (CAR-T cells) that target and calm the immune attack on the pancreas in people with early type 1 diabetes. The goal is to preserve the body's own insulin-making cells and reduce the need for injected insulin. Nine adults aged 18–40 with newly diagnosed or early-stage type 1 diabetes will be enrolled to check safety and see if the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T1DM - TYPE 1 DIABETES MELLITUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, 201508, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.